key: cord-0854976-2kvlfmf9
authors: Hetrick, Brian; Chilin, Linda D.; He, Sijia; Dabbagh, Deemah; Alem, Farhang; Narayanan, Aarthi; Luchini, Alessandra; Li, Tuanjie; Liu, Xuefeng; Copeland, Joshua; Pak, Angela; Cunningham, Tshaka; Liotta, Lance; Petricoin, Emanuel F.; Andalibi, Ali; Wu, Yuntao
title: Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs
date: 2022-02-24
journal: Cell Rep Methods
DOI: 10.1016/j.crmeth.2022.100181
sha: 424fde0ed8ed2bc27c572bb0ef5c9f7d7fe0b189
doc_id: 854976
cord_uid: 2kvlfmf9

SARS-CoV-2 spike protein (S) pseudotyped viruses are commonly used for quantifying antiviral drugs and neutralizing antibodies. Here we describe the development of a hybrid alphavirus-SARS-CoV-2 pseudovirion (Ha-CoV-2), which is a non-replicating SARS-CoV-2 virus-like particle composed of viral structural proteins (S, M, N, and E) and a RNA genome derived from a fast expressing alphaviral vector. We validated Ha-CoV-2 for rapid quantification of neutralization antibodies, antiviral drugs, and viral variants (e.g. delta). In addition, as a proof-of-concept, we used Ha-CoV-2 to quantified the neutralizing antibodies from an infected and vaccinated individual, and found that the one dose vaccination with Moderna mRNA-1273 has greatly increased the anti-serum titer for approximately 6 fold. The post-vaccination serum can neutralize all 9 variants tested. These results demonstrate that Ha-CoV-2 can be used as a robust platform for rapid quantification of neutralizing antibodies against SARS-CoV-2 and its emerging variants.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly spreading, novel beta-coronavirus that is causing the ongoing global pandemic of coronavirus disease 2019 (Gorbalenya et al., 2020; Wu et al., 2020a; Wu et al., 2020b; Zhou et al., 2020; Zhu et al., 2020) . SARS-CoV-2 has caused over 183 million infections and 4 million deaths globally as of July 2021. Antiviral drugs and neutralizing antibodies are effective to combat the pandemic. In particular, neutralizing antibodies, induced by vaccines or by the virus, can play a critical role in controlling and preventing infection. Currently, only one FDA-approved drug, remdesivir, is available to reduce hospital stay (Beigel et al., 2020) ; several vaccines have recently shown significant results in phase III clinical trials (Jackson et al., 2020; Palacios et al., 2020; Polack et al., 2020; Ramasamy et al.; Voysey et al.) , and been approved for emergency use. Nevertheless, the effectiveness of vaccines needs to be continuously monitored for the induction of neutralizing antibodies against evolving viral variants.

Current antiviral drug screening and quantification of neutralizing antibodies rely on the use of SARS-CoV-2 pseudoviruses (Corbett et al., 2020; Dieterle et al., 2020; Nie et al., 2020a, b; Riva et al., 2020; Schmidt et al., 2020; Whitt, 2010; Yang et al., 2020) . The use of live virus requires biosafety level (BSL) 3 facility and practice, which limits large-scale testing and analyses in common laboratories. Both lentivirus and vesicular stomatitis virus (VSV), pseudotyped with the SARS-CoV-2 S protein, are used in cell-based neutralization assays and in antiviral drug screening (Dieterle et al., 2020; Nie et al., 2020a, b; Yang et al., 2020) . SARS-CoV-2 contains four structural proteins: the spike protein (S), the membrane protein (M), the envelope protein (E), and the nucleocapsid protein (N) (Siu et al., 2008; Yoshimoto, 2020) . S is the major viral protein responsible for virus attachment and entry to target cells (Cai et al., 2020;  J o u r n a l P r e -p r o o f Huang et al., 2020; Walls et al., 2020) , and thus, is commonly used to pseudotype viruses.

Nevertheless, both VSV-and lentiviral-based pseudoviral particles contain only the S protein, and the major structural components are non-SARS-CoV-2 proteins, which may affect virion properties in receptor binding and responses to antibody neutralization (He et al., 2021) . In addition, an important issue for the VSV-based pseudovirus is the presence of residual VSV virus, which can result in high rates of false-positive results (Li et al., 2018) . To improve the VSV-based system, highly infectious, recombinant, replication-competent VSV-SARS-CoV-2 viruses have recently been constructed (Case et al., 2020; Dieterle et al., 2020) , and shown to express GFP signals as fast as 7.5 hours from multiple rounds of viral replication. The systems have been used to quantify neutralizing antibodies and ACE2 inhibitors (Case et al., 2020) .

Nevertheless, the pathogenic potential of the recombinant, replication-competent VSV-SARS-CoV-2 virus has not been fully investigated, and large-scale production of the new infectious particles may require high bio-containment environment. In addition, the production of viral particles through multiple rounds of viral replication may generate unwanted viral mutations and variants, requiring vigorous screening and validation.

The use of single-entry, non-replicating lenti-or VSV-based pseudoviruses has the safety advantage, and a well-controlled course in particle production through DNA transfection.

However, for antibody neutralization assays, the use of these particles is time consuming in general, requiring 2 to 3 days to infect and generate reporter signals (Dieterle et al., 2020; Nie et al., 2020a, b; Whitt, 2010; Yang et al., 2020) . To overcome the limitations of current pseudoviruses, here we describe the development and validation of a new hybrid alphavirus-SARS-CoV-2 particle (Ha-CoV-2) for rapid quantification of neutralization antibodies and antiviral drugs. Ha-CoV-2 is a non-replicating SARS-CoV-2 virus-like particle that is composed J o u r n a l P r e -p r o o f of authentic virus structural proteins (S, M, N, and E) from SARS-CoV-2 with no structural proteins from other virus. Ha-CoV-2 also contains a genome derived from an alphavirus-based vector (Ciccarone et al., 1998; Wengler, 1980) , which can rapidly and robustly express reporter genes within a few hours after viral entry (Wengler, 1980) . In this study, we demonstrate that Ha-CoV-2 can be used as a robust platform for rapid quantification of neutralization antibodies, viral variants, and antiviral drugs.

To establish a rapid cell-based SARS-CoV-2 infection system for screening and evaluation of neutralizing antibodies and antiviral drugs, we developed a new hybrid alphavirus-SARS-CoV-2 viral particle, in which an alphavirus-based RNA genome is enclosed for rapid expression of reporter genes in target cells ( Figure 1A) . The genomic RNA consists of the 5' untranslated region and open-reading frames coding for the nonstructural proteins (nsp) 1-4 from Semliki Forest virus (SFV) (Ciccarone et al., 1998; Liljeström and Garoff, 1991) ; the inclusion of nsp1-4 allows for self-amplification of the RNA genome in cells. The RNA genome also contains viral subgenomic RNA promoters for the expression of reporter genes (such as firefly luciferase, Luc).

The 3' end of the genome contains the 3' untranslated region of SFV and a poly(A) tail that are used to stabilize RNA. In addition, a putative SARS-CoV-2 packaging signal was inserted downstream of the reporter gene to facilitate RNA packaging by the SARS-CoV-2 structural protein N (Hsieh et al., 2005; Lu et al., 2021; Woo et al., 2019) . To assemble viral particles, we used the DNA vector, Ha-CoV-2, to express the genomic RNA. The Ha-CoV-2 vector was cotransfected with vectors expressing the structural proteins of SARS-CoV-2 (S, M, E, and N) into HEK293T cells ( Figure 1A) . Virion particles were harvested at 48 hours post J o u r n a l P r e -p r o o f cotransfection, and tested for virion infectivity and the ability to express reporter genes in target cells. First, to confirm the presence of the SARS-CoV-2 structural proteins in Ha-CoV-2 particles, we performed western blots of purified particles, using antibodies against the S protein of SARS-CoV-2. We were able to detect the presence of S in Ha-CoV-2 particles ( Figure 1B) .

To further determine the presence of the other structural proteins of SARS-CoV-2, we also assembled Ha-CoV-2 particles using FLAG-tagged M and N proteins, and performed western blots using anti-FLAG antibodies. We were able to confirm the presence of both M and N in Ha-CoV-2 particles ( Figure 1C and 1D) . Furthermore, to determine whether these structural proteins are present in the same virion particles, we used anti-S antibody-conjugated magnetic beads to pull down Ha-CoV-2 particles. The magnetically separated particles were further examined with western blot using the anti-FLAG antibody for the presence of FLAG-tagged M protein. As shown in Figure 1E , we detected the presence of M in the anti-S antibody pull-down particles, confirming that cotransfection of the SARS-CoV-2 structural proteins with the Ha-CoV-2 vector led to the production of SARS-CoV-2 virus-like particles (VLPs).

To further demonstrate the ability of Ha-CoV-2 particles to infect and express reporter genes in target cells, we assembled an Ha-CoV-2(GFP) reporter virus, and used it to infect HEK293T(ACE/TEMPRSS2) cells that overexpressed both ACE2 and TMPRSS2. We observed GFP expression in cells following infection (Figure 2A) , demonstrating that the alphavirusbased RNA genome can be packaged by the budding SARS-CoV-2 VLPs, and is capable of expressing the GFP reporter gene in target cells. To determine whether the infection of target cells by Ha-CoV-2 is dependent on the interaction of S with the ACE2 receptor (Li et al., 2003; Zhou et al., 2020) , we assembled an Ha-CoV-2(Luc) reporter virus and used it to simultaneously infect HEK293T(ACE/TEMPRSS2) cells and the parent HEK293T cell. As shown in Figure 2B , J o u r n a l P r e -p r o o f Ha-CoV-2(Luc) expressed high-levels of Luc in the HEK293T(ACE/TEMPRSS2) cells but minimal levels of Luc in HEK293T, demonstrating the requirement of ACE2 for Ha-CoV-2 infection. We further confirmed the requirement for S-ACE2 interaction by generating particles without the S protein. As shown in Figure 2C , in the absence of S, Luc expression was highly diminished, demonstrating the requirement of S for Ha-CoV-2 infection. We also tested the requirement for the other structural proteins, M, N, and E, for Ha-CoV-2 infection. Although these proteins were found to be nonessential, removal of M, N, and E led to a reduction in Ha-CoV-2 infection ( Figure 2C ). We further investigated the individual contributions of M, N, and E for Ha-CoV-2 infection. It appeared that in general, particles assembled with two or three of these structural proteins gave rise to a higher level of infection than those with only one protein.

However, the presence of S plus E appears to be sufficient for the full infectivity of Ha-CoV-2 ( Figure 2D) .

A major advantage of utilizing alphavirus-based RNA genome for Ha-CoV-2 is the extremely fast speed and high-level gene expression of alphaviruses; gene expression from the subgenomic RNA promoters occur within hours of infection, and levels of viral plus-RNAs can reach 200,000 copies in a single cell (Ciccarone et al., 1998; Wengler, 1980) . We followed the time course of Ha-CoV-2(Luc) infection, and observed that the Luc reporter expression increased rapidly within 6 hours from the addition of particles to cells (Figure 3 ). This rapid reporter expression kinetics permitted us to utilize Ha-CoV-2 for fast screening and quantification of neutralization antibodies and anti-viral drugs.

Lenti-based SARS-CoV-2 pseudoviruses have been commonly used for antiviral drug screening and neutralization antibody assays (Schmidt et al., 2020; Yang et al., 2020) . We performed a comparison of Ha-CoV-2 with lenti-pseudovirus for the infection of both ACE2-J o u r n a l P r e -p r o o f overexpressing cells and cells expressing native levels of ACE2. Lenti-pseudovirus and Ha-CoV-2 particles were assembled in similar cell culture conditions, and an equal volume of the particles was used for infection. Both lenti-pseudovirus and Ha-CoV-2 can infect the ACE2overexpressing HEK293T(ACE2/TMPRESS2) cells ( Figure 4A) . However, infection of Calu-3, a human lung cancer cells expressing native levels of ACE2, was minimal with the lentipseudovirus (He et al., 2021) , whereas Ha-CoV-2 particles produced much higher signal for the infection of Calu-3 cells ( Figure 4B ). Infection of primary human ACE2-null monkey kidney cells with Ha-CoV-2 did not generate signals above uninfected cell background ( Figure 4C ).

These results demonstrate that Ha-CoV-2 is likely more sensitive for the infection of low ACE2expressing cells.

We further followed an infection time course of Ha-CoV-2, and compared it with the infection course of the lenti-pseudovirus. As shown in Figure 4D , in Ha-CoV-2 infection, Luc reporter expression became detectable as early as 2 to 4 hours, whereas in the lenti-pseudovirus infection, Luc reporter expression was detectable only after 24 hours. In addition, the reporter expression in Ha-CoV-2 infection was much robust; by 24 hours, it reached a level approximately150 fold higher than that generated from the lenti-pseudovirus infection in our assay system.

To validate Ha-CoV-2 for rapid screening and quantification of neutralizing antibodies, we tested an anti-SARS-CoV-2 antiserum (1F), which was serially diluted and pre-incubated with Ha-CoV-2(Luc). The antibody-virus complex was used to infect cells for 5 hours for Luc expression. As shown in Figure 5A , we observed 1F concentration-dependent inhibition of Ha-CoV-2(Luc), and the IC50 was determined to be at 1:433 dilution ( Figure 5A ). Given that SARS-CoV-2 lenti-pseudoviruses have been widely used in neutralization assays (Jackson et al., J o u r n a l P r e -p r o o f 2020; Nie et al., 2020b; Schmidt et al., 2020) , we also performed a similar assay using 1F and a lenti-pseudovirus, Lenti-SARS-CoV-2(Luc) (He et al., 2021) . Infected cells were analyzed at 72 hours post infection. We observed similar 1F concentration-dependent inhibition of the lentipseudovirus, and the IC50 was found to be at 1:186 dilution ( Figure 5B ). These results were confirmed using anti-sera from multiple donors (Figure S1 ), and demonstrated that Ha-CoV-2 is as effective as lenti-pseudoviruses for quantifying neutralizing antibodies, but with a much faster speed (5-12 hours versus 48-72 hours).

Based on the 1F results described above, we performed additional validation of Ha-CoV-2based neutralizing assays using convalescent plasma from 19 donors. The inhibition curve and IC50 of each serum are presented in Figure 5C . For comparison, an independent quantification was conducted using infectious SARS-CoV-2 to validate these anti-sera. We observed a direct correlation (r 2 = 0.87) in the IC50 values obtained from Ha-CoV-2 and from SARS-CoV-2 ( Figure 5D ). These results demonstrated that Ha-CoV-2 can be used for rapid quantification of neutralizing antibodies.

Pseudoviruses have also been commonly used for high throughput screening of SARS-CoV-2 entry inhibitors (Whitt, 2010; Yang et al., 2020) . We tested a broad-spectrum viral entry inhibitor, Arbidol (Umifenovir) (Boriskin et al., 2008) , for its ability to block Ha-CoV-2(Luc) infection. As shown in Figure 5E , we observed dosage-dependent inhibition of Ha-CoV-2(Luc) in 5 hours, and the IC50 was determined to be 16 µM. In addition, we also tested a TMPRSS2 protease inhibitor camostat mesylate, and confirmed that it inhibited Ha-CoV-2 infection of HEK293T(ACE2/TMPRSS2) cells at a high dosage (1 mM) ( Figure S2 ) (Hoffmann et al., 2021) . These results demonstrated that Ha-CoV-2 can be used for rapid screening of SARS-CoV-2 entry inhibitors.

Finally, we investigated whether the Ha-CoV-2 system can be used for rapid evaluation of relative infectivity of viral variants. The D614G spike mutation emerged early in the COVID-19 pandemic, and has recently been reported to confer greater infectivity that has led to the global dominance of the D614G mutant in circulation (Isabel et al., 2020; Korber et al., 2020) . To determine whether the increase in virus infectivity can be recapitulated and quantified by the Ha-CoV-2 system, we assembled Ha-CoV-2 particles using the G614 mutant S protein (G614) or the parental S protein (D614). We found that the D614G mutation did not increase virion release or the level of S protein virion incorporation ( Figure 6A and 6B) . However, Ha-CoV-2 particles bearing the G614 spike were found to be nearly 3 times more infectious than those bearing the D614 spike ( Figure 6C ).

We further assembled additional 13 Ha-CoV-2(Luc) isolates derived from circulating SARS-CoV-2 variants (selected from the GISAID global reference database, . Ha-CoV-2(Luc) and the related S protein variants were used to infect target cells, and the relative infectivity was quantified. As shown in Figure 6D , when normalized with the genomic RNA copies, these variants in general are 2-10 fold more infectious than the original parental Ha-CoV-2(Luc). These results demonstrated that Ha-CoV-2 can provide a convenient tool for rapid monitoring and quantification of viral variants. As a proof-of-concept, we further quantified the ability of an anti-serum to neutralize viral variants. We acquired convalescent plasma from a donor who was infected, and then vaccinated with one dose Moderna mRNA-1273. This one dose vaccination has greatly increased the anti-serum titer for approximately 6 fold ( Figure 6E) . Furthermore, when Ha-CoV-2(Luc) variants were tested, we found that the post-vaccination serum had neutralizing activities against J o u r n a l P r e -p r o o f all variants tested ( Figure 6F) . Nevertheless, the neutralizing activities differ greatly among the variants; the anti-serum has the highest neutralizing activity against B.1.494 (IC50, 1: 6872), and lowest activity against the B.1.1.429 variant (IC50, 1:1106). These results demonstrate that Ha-CoV-2 can be used for rapid quantification of SARS-CoV-2 variants for potential impacts on neutralizing antibodies and vaccine effectiveness

The study of SARS-CoV-2 requires high-level containment that limits the use of infectious virus in common clinical and research laboratories. Pseudoviruses and virus-like particles (VLPs) have been widely used for SARS-CoV-2 drug discovery and vaccine development. Pseudoviruses, such as those derived from lentivirus and vesicular stomatitis virus, can mimic the entry process of SARS-CoV-2. However, structurally, they are very different from SARA-CoV-2 and lack structural components provided by M, E, and N of SARS-CoV-2. VLPs closely resemble SARS-CoV-2 particles, but VLPs contain no genome for reporter expression in target cells . In this article, we described the development and validation of a novel hybrid system, the Ha-CoV-2 particle, which is structurally a VLP, but possesses the ability of a pseudovirus to enter and express reporter genes in target cells.

Ha-CoV-2 also contains a reporter genome derived from the robust expression system of alphavirus, and our results are consistent with previous studies of alphaviral vectors. The high efficiency and rapid gene expression capacity of alphaviral vectors have been well documented by multiple previous studies. For example, Hahn et al has demonstrated that an alphaviral vector can effectively produce high titer particles (10 8 -10 9 PFU/ml) in transfected cells, and generate >10 6 CAT (chloramphenicol acetyltransferase) reporter molecules within 7 hours after infection J o u r n a l P r e -p r o o f of target cells (Hahn et al., 1992) . Xiong et al. have also demonstrated that an alphaviral vector can efficiently and rapidly express 10 8 CAT per cell in 16-20 hours (Xiong et al., 1989) . As well, gene expression from the subgenomic RNA promoters can occur within hours of infection, and levels of viral plus-RNAs can reach 200,000 copies in a single cell (Ciccarone et al., 1998; Wengler, 1980) . In addition, alphavirus-based virus-like vesicles have been used for rapid and efficient expression of VSV glycolprotein (Kelly et al., 2008; Rolls et al., 1994; Rose et al., 2014; Rose et al., 2008; Schell et al., 2011) and hepatitis B virus antigens (Yarovinsky et al., 2019) .

We further demonstrated that Ha-CoV-2 can be used for rapid screening and quantification of neutralization antibodies, viral variants, and antiviral drugs. We also performed a direct comparison between Ha-CoV-2 and a lenti-pseudovirus in antibody neutralization assays. While both systems are effective in quantifying neutralizing antibodies, the sensitivity of the two systems differs (Figure 5A , 5B, and Figure S2 ). The lenti-pseudovirus contains only the S protein of SARS-CoV-2, whereas Ha-CoV-2 contains all four structural proteins (S, M, E, and N) of SARS-CoV-2, and has no structural proteins from other viruses (e.g. gag and pol of lentivirus). Although S is the primary requirement for viral entry, the presence of other structural proteins of SARS-CoV-2 may also affect virion infectivity and particle interaction with cell membrane and antibodies. In our system, the lack of M and E on virion particles does appear to affect virus infection (Fig. 2D) .

The membrane glycoprotein (M) in particular is the most abundant protein in SARS-CoV-2 virions, and M has a SemiSWEET sugar transporter-like structure, suggesting that it may influence the glycosylation of the S protein and S interaction with antibodies (Thomas, 2020) . In addition, the N-terminus of M in CoVs has a glycosylated ectodomain that protrudes outside the virion and interacts with S, N, and E; it has been shown that SARS-CoV anti-M antibodies can synergize with anti-S and anti-N antibodies for improved neutralization (Pang et al., 2004; J o u r n a l P r e -p r o o f al., 2006) , and M has also been used in protective SARS-CoV and MERS-CoV vaccines (Ong et al., 2020) . These previous studies suggest that M may affect the neutralizing activities of the anti-S antibody. In our study, we have compared Ha-CoV-2(Luc) (S only) particles with Ha-CoV-2(Luc) (S+M+N+E) particles for their sensitivity to neutralizing antibodies (Figure S3) , and found that there was a great correlation (R 2 = 0.892). However, the Ha-CoV-2(Luc) (S only) particle was found to be slight more sensitive to antibody neutralization ( Figure S3) . The mechanism is unknown, but could be related to the lower infectivity or stability of the Ha-CoV-2(Luc) (S only) particles, which may be more sensitive to inactivation by antibody binding.

We also compared Ha-CoV-2 with infectious SARS-CoV-2, and observed a good direct correlation (R 2 = 0.87) for antibody quantification, validating that Ha-CoV-2 can serve as a surrogate of SARS-CoV-2 for neutralizing antibody quantification (Fig. 5D) . However, the SARS-CoV-2-based plaque reduction assay has a higher sensitivity than pseudoviruse-base assays in general (Nie et al., 2020a; Yang et al., 2020) . One possible reason may be that SARS-CoV-2 virus is produced from infection and productive virus replication, and likely contains high percentages of infectious particles, whereas for pseudoviruses, they are assembled by cotransfection in sub-optimal conditions with only one or a few SARS-CoV-2 structural proteins, and likely contain large amounts of defective particles. Non-infectious defective particles may also bind to antibodies, reducing effective antibody concentrations.

In addition to viral structural proteins, virion particles also incorporate multiple cellular proteins during virion budding and release. Many of these cellular factors such as PSGL-1 can impact virion infectivity (Fu et al., 2020; He et al., 2021; Liu et al., 2019; Murakami et al., 2020) and antibody binding to plasma membrane (Umeki et al., 2013) . SARS-CoV-2 budding occurs mainly at the membranes of ER-Golgi intermediate compartment (V'kovski et al., 2020) ,

whereas the lenti-pseudovirus buds from the plasma membrane (Freed, 2015) . Because of the difference, it is possible that different sets of cellular proteins may be incorporated into lentipseudovirus and SARS-CoV-2. In this regard, the close resemblance of Ha-CoV-2 particle to SARS-CoV-2 may provide a unique tool for studying effects of virion host proteins in SARS-CoV-2 infection and pathogenesis (He et al., 2021) .

As SARS-CoV-2 continues to circulate and evolve, viral variants pose a particular challenge for the control of the COVID-19 pandemic, as documented in the recent emergence of the B.1.1.7 lineage in UK (Rambaut et al., 2020) . Viral mutation may lead to increases in viral transmission and fitness, and thus there is an urgent need for rapid identification and characterization of emerging variants for changes in viral infectivity and responses to neutralizing antibodies. The

Ha-CoV-2 system would provide a robust platform for rapid quantification of viral variants and potential impacts on neutralizing antibodies and vaccine effectiveness.

The present method does have some limitations. For one, Ha-CoV-2 based assays are mostly performed on HEK293T cells that over-express the human ACE2 and TMPRESS2 receptors.

Certainly human primary cells expressing low-levels of ACE2 may require the use of infection enhancer to acquire robust signals.

The authors wish to thank Janice Yoon for technical assistance. Dr. Pei-Hui Wang for providing 

• Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Yuntao Wu (ywu8@gmu.edu).

• All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

• All data generated or analyzed during this study are included in this article. Data reported in this paper will be shared by the lead contact upon request.

• This paper does not report original code.

• Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

The study involved the use of human serum from adult donors. Donor gender identity information was kept confidential per protocols and there is no scientific basis for gender preference in donor selection. Informed consent was obtained from all subjects. All protocols involving human subjects were reviewed and approved by the George Mason University institutional review board (GMU IRB Protocol No. 1592168-9) .

J o u r n a l P r e -p r o o f

The SARS-CoV-2 S, S(D614G), M, E, or N expression vectors were purchased from

Sinobiological. The Ha-CoV-2(Luc) and Ha-CoV-2(GFP) vectors, and the S protein variants were selected from isolates identified in the GISAID global database (Table 1) S expression vector (0.5 μg), pCMVΔR8.2 (7.5 μg), and pLTR-Tat-IRES-Luc (10 μg) as previously described (He et al., 2021) .

The SARS-CoV-2 M-FLAG and N-FLAG vectors were kindly provided by Dr. Pei-Hui Wang . HEK293T cells were co-transfected with 10 μg Ha-CoV-2(Luc), 2.5 μg of the SARS-CoV-2 S expression vector, and 2.5 μg each of the M-FLAG, N-FLAG, and E-FLAG Viral titer of SARS-CoV-2 was determined by counting the number of plaques.

Arbidol-hydrochloride (Sigma) was resuspended in Dimethyl sulfoxide (Sigma).

HEK293T(ACE2/TMPRSS2) cells were pretreated for 1 hour with serially diluted Arbidol. Ha-CoV-2 particles were added to cells, followed by the addition of Abidol to maintain the drug concentration. Cells were infected in the presence of Arbidol for 2 hours, washed, and then cultured in fresh medium for a total of 5 hours. Cells were lysed in Luciferase Assay Lysis Buffer (Promega) for luciferase assays using GloMax Discover Microplate Reader (Promega).

Camostat Mesylate (Millipore Sigma) was resuspended in Dimethyl sulfoxide (Millipore Sigma).

Cells were pretreated for 1 hour with serially diluted Camostat Mesylate. Ha-CoV-2 particles were added to cells, followed by the addition of Camostat Mesylate to maintain the drug concentration. Cells were infected in the presence of Camostat Mesylate for 18 hours. Cells were lysed in Luciferase Assay Lysis Buffer (GoldBio) for luciferase assays using GloMax Discover Microplate Reader.

J o u r n a l P r e -p r o o f

The study contains a large number of direct quantification of assay values (luciferase activity quantified by luciferase assay reading), but only basic statistic concept (mean and standard deviation) were used to describe these results. Infection and luciferase assays were performed in triplicate as indicated in the figure legends (Figures 2, 3, 4 and 6) . Luciferase expression was quantified with luciferase assay and the mean was the average value of the three luciferase assay readings. Standard deviation (SD) were determined using Microsoft Excel. Antibody neutralization activity was plotted using GraphPad Prism 7 and the IC50 values were calculated using GraphPad Prism 7. 

Remdesivir for the Treatment of Covid-19 -Final Report

Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion

Distinct conformational states of SARS-CoV-2 spike protein

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

The SFV Gene Expression System

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition

HIV-1 assembly, release and maturation

PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses

Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation

PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity Viruses

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Human macrophages support persistent transcription from unintegrated HIV-1 DNA

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Current status on the development of pseudoviruses for enveloped viruses

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

Proteomic profiling of HIV-1 infection of human CD4(+) T cells identifies PSGL-1 as an HIV restriction factor

The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning

Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial

Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA

In vitro evolution of high-titer, virus-like vesicles containing a single structural protein

Hybrid alphavirusrhabdovirus propagating replicon particles are versatile and potent vaccine vectors

Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization

The M, E, and N Structural Proteins of the Severe Acute Respiratory Syndrome Coronavirus Are Required for Efficient Assembly, Trafficking, and Release of Virus-Like Particles

The Structure of the Membrane Protein of SARS-CoV-2 Resembles the Sugar Transporter SemiSWEET

Anti-adhesive property of P-selectin glycoprotein ligand-1 (PSGL-1) due to steric hindrance effect

Coronavirus biology and replication: implications for SARS-CoV-2

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

16 -Effects of Alphaviruses on Host Cell Macromolecular Synthesis

Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

An in vivo cell-based assay for investigating the specific interaction between the SARS-CoV N-protein and its viral RNA packaging sequence

A new coronavirus associated with human respiratory disease in China

SARS-CoV-2 is an appropriate name for the new coronavirus

Sindbis virus: an efficient, broad host range vector for gene expression in animal cells

Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System

Development and effectiveness of Pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro

Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

Shown are the concentration-dependent inhibition curves by the anti-sera, which were serially diluted and incubated with Ha-CoV-2(Luc) particles for 1 hour at 37°C. The Ha-CoV-2(Luc)-antibody complex was used to infect HEK293T(ACE2/TMPRSS2) cells. Neutralization activities were quantified by luciferase assay at 18 hours post addition of virus to cells. Control serum was a monoclonal rabbit anti-SARS-CoV-2 S protein RBD antibody. (B) Quantification of neutralizing antibodies with Ha-CoV-2(Luc) (S+M+N+E) particles. Shown are the concentration-dependent inhibition curves by the anti-sera, which were serially diluted and incubated with Ha-CoV-2(Luc) (S+M+N+E) particles for 1 hour at 37°C. The Ha-CoV-2(Luc)antibody complex was used to infect HEK293T(ACE2/TMPRSS2) cells. Neutralization activities were quantified by luciferase assay at 18 hours post addition of virus to cells. Control serum was a monoclonal rabbit anti-SARS-CoV-